On Tuesday, Viridian Therapeutics Inc (NASDAQ: VRDN) opened higher 4.80% from the last session, before settling in for the closing price of $13.13. Price fluctuations for VRDN have ranged from $9.90 to $27.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -4.11%. Company’s average yearly earnings per share was noted -6.05% at the time writing. With a float of $73.51 million, this company’s outstanding shares have now reached $80.99 million.
Let’s determine the extent of company efficiency that accounts for 143 employees. In terms of profitability, gross margin is -1931.79%, operating margin of -99018.54%, and the pretax margin is -89387.09%.
Viridian Therapeutics Inc (VRDN) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Viridian Therapeutics Inc is 9.79%, while institutional ownership is 104.69%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.98 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.74% during the next five years compared to 31.28% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Check out the current performance indicators for Viridian Therapeutics Inc (VRDN). In the past quarter, the stock posted a quick ratio of 15.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3737.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.77, a number that is poised to hit -0.97 in the next quarter and is forecasted to reach -3.96 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Looking closely at Viridian Therapeutics Inc (NASDAQ: VRDN), its last 5-days average volume was 1.26 million, which is a jump from its year-to-date volume of 1.05 million. As of the previous 9 days, the stock’s Stochastic %D was 79.63%. Additionally, its Average True Range was 1.04.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 28.07%, which indicates a significant decrease from 89.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.50% in the past 14 days, which was higher than the 64.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.76, while its 200-day Moving Average is $18.05. However, in the short run, Viridian Therapeutics Inc’s stock first resistance to watch stands at $14.00. Second resistance stands at $14.23. The third major resistance level sits at $14.61. If the price goes on to break the first support level at $13.39, it is likely to go to the next support level at $13.01. Should the price break the second support level, the third support level stands at $12.78.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
There are currently 81,485K shares outstanding in the company with a market cap of 1.12 billion. Presently, the company’s annual sales total 300 K according to its annual income of -269,950 K. Last quarter, the company’s sales amounted to 70 K and its income totaled -79,730 K.
